1Packer H. Beta-adrenergic blockade in chronic heart failare: principles ,progress, and practice [ J]. Prog Cardiovasc Dis, 1998,41 [ Suppl1 ] : 39-52.
2Bfistow MR. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents[J]. Am J Cardiol, 1993,71 (9) : 12c-22c.
3Esler M, Kaye D, Lumbere G, et al. Adrenergic nervous system in heart failure [ J]. Am J Cardiol, 1997,80[ Suppl ] : 7L.
4Bristow MR. Mechanism of action of beta-blocking agent in heart failure[ J]. Am J Cardol, 1997,80(11A) :26L-40L.
5Waigatein F, Bfintow MR, Swedberg K, et al. Beneficial effect of meroprolol in idiopathic dilated cardiocnyopathy [ J ]. Lancet, 1993, 342(8885) : 1441-1446.
6CIBIS Investigators and commtees. A randomiced trial of β blockade in heart failure the Cardic Insufficiency Bisoprolol Study(CIBIS) [ J]. Circulation, 1994,90(4) : 1765.
7Packer M, Coats A J, Fowler MB. Effect of carvedilol on survival in severe chronic heart failure [ J ]. N Engl J Med, 2001,344 (22) : 1651-1658.
8Dargie HJ. Effect of carvedilol on outcome after myocarkial infarction in patients with left-ventricular dysfunction:the CAPRICORN randomized trial[ J]. Lancet ,2001,357(9266) : 1385-1390.
9Packer M, Bfistow M, Cohn J, et al .The effect of carvedilol on morbidity and mortality in patients with chronic heart failare [ J ]. N Engl J Med, 1996,334(20) : 1349-1355.
10The Australia-New Zealand carvedilol study heart failure research collaborative group. Randomised Placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease[J]. Lancet, 1997,349(9049) :375-380.
3Loirand G,Guerin P,Pacaus P.Rho kinases in cardiovascular phygiolgy and Pathophysiology[J]. Oire Res, 2006,98(5) : 522-334.
4Komers R,Oyama TT,Beard DR,et al.Eefects of systemic inhibition of Rho Kinade on blood pressure and renal haemodynamies in diabctic rats[J]. 8r J Pharmacol,2011,42(2):100-104.
